A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Criteria

Inclusion Criteria:

• Pathologically documented, locally-advanced or metastatic malignancy

• Standard treatment is not available or patient declines

• Adequate organ function

Exclusion Criteria:

• Active brain metastases from non-brain tumors.

• Gastrointestinal (GI) tract disease causing the inability to take oral medication.

• Other protocol specified criteria